Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Penny Fleck as chief ...
In September, ONL announced the closing of a $65 million Series D financing round, led by Johnson & Johnson Innovation – JJDC, Inc. The Series D funding supports the advancement of the development of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback